Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Hedgehog signaling pathway" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The Hedgehog signaling pathway is a signaling pathway that transmits information to embryonic cells required for proper cell differentiation. Different parts of the embryo have different concentrations of hedgehog signaling proteins. The pathway also has roles in the adult. Diseases associated with the malfunction of this pathway include basal cell carcinoma.
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS7517870B2High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
Owner:FOND AZIONE TELETHON
Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.
Owner:ABRAXIS BIOSCI LLC
Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
InactiveUS20130045240A1Organic active ingredientsPowder deliveryHedgehog signaling pathwayNanoparticle
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.
Owner:ABRAXIS BIOSCI LLC
Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS20060276391A1High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).
Owner:FOND AZIONE TELETHON
Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
Owner:NOVARTIS AG
Compounds and compositions as hedgehog pathway modulators
Owner:SUN PHARMA INDS
Mediators of hedgehog signaling pathways, compositions and uses related thereto
InactiveUS20050014796A1Increase hedgehog-dependent transcriptional activationUpregulationBiocideOrganic chemistryHedgehog signaling pathwayAgonist
The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Owner:CURIS INC
Mediators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto
InactiveUS20090012082A1Inhibits ptc loss-of-functionSmoothened gain-of-functionBiocideSenses disorderHedgehog signaling pathwayBiology
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Owner:GENENTECH INC
Compounds and compositions as hedgehog pathway inhibitors
The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
Owner:NOVARTIS AG
Hedgehog pathway modulators
The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
Owner:NOVARTIS AG
Mediators of hedgehog signaling pathways, compositions and uses related thereto
InactiveCN101007802AInhibition of abnormal growth stateCosmetic preparationsOrganic chemistryHedgehog signaling pathwayBiology
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g.,to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Owner:CURIS INC
Method of inhibiting dyrk1b
ActiveUS20140371251A1Preventing formation of resistanceGood for healthOrganic active ingredientsBiocideHedgehog signaling pathwayG protein-coupled receptor
The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and / or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
Owner:4SC
Smoothened antagonism for the treatment of hedgehog pathway-related disorders
The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and / or Phosphatidylinositol 3-kinase (PI3K) inhibitors.
Owner:NOVARTIS AG
Compounds and compositions as hedgehog pathway modulators
InactiveUS20090209573A1High proliferation rateReduced expression levelBiocideTissue cultureHedgehog signaling pathwayPhenotype
The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Owner:IRM +1
Mediators of hedgehog signaling pathways, compositions and uses related thereto
InactiveUS7816369B2Inhibits ptc loss-of-functionSmoothened gain-of-functionBiocideSenses disorderHedgehog signaling pathwayBiology
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Owner:GENENTECH INC
Method of inhibiting DYRK1B
ActiveUS9951050B2Good for healthImprove progressOrganic active ingredientsOrganic chemistryHedgehog signaling pathwayG protein-coupled receptor
The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and / or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
Owner:4SC
Hedgehog signal pathway gene associated with amputated limb regeneration of Periplaneta americana and application of dsRNA thereof
ActiveCN109207601AInhibition of regenerative capacity of amputated limbsEfficient removalBiocideMicrobiological testing/measurementHedgehog signaling pathwayPest control
The invention discloses a hedgehog signal pathway gene associated with amputated limb regeneration of Periplaneta americana and application of dsRNA thereof. The results showed that Hh gene, Ptc gene,Smo gene and / or Ci gene had the ability to affect the limb regeneration of Periplaneta americana. Moreover, silencing the expression of Hh, Ptc, Smo and Ci genes could inhibit the regeneration ability of Periplaneta americana, which could not only remove the pests of Periplaneta americana efficiently, but also avoid the environmental pollution and is safe and reliable. Hh, Ptc, Smo and Ci gene ofthat invention can be used as control target of Periplaneta americana pest control.
Owner:MEIZHOU HUASHENG GUANGMEI BIOTECHNOLOGY CO LTD
Compounds and compositions as HEDGEHOG signaling pathway modulators
The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Owner:IRM
Itraconazole analogues and methods of use thereof
ActiveUS9650365B2Organic active ingredientsOrganic chemistryHedgehog signaling pathwayAngiogenesis growth factor
Disclosed herein are analogs of itraconazole that are both angiogenesis and hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.
Owner:UNIV OF CONNECTICUT
Use of hedgehog agonists in the treatment of musculoskeletal-related disorders
InactiveCN101932313AOrganic active ingredientsMuscular disorderDuchenne muscular dystrophyHedgehog signaling pathway
The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize Sonic Hedgehog (shh), and thereby, the Hedgehog signaling pathway. Said agonizing agents include, e.g., the compounds of the invention (e.g., a compound of Formula I). The invention also provides methods of screening for agents that are capable of increases the proliferation of muscle and / or muscle precursor cells.
Owner:NOVARTIS AG
Modulation of hedgehog-mediated signaling pathway
The present invention provides transcription factors associated with the hedgehog signaling pathway that are regulated by dephosphorylation by phosphatases. Hedgehog response elements (HRE) that interact with the dephosphorylated transcription factors are also provided as well as methods for identifying compounds that are phosphatase inhibitors. Methods of treating tumors in a subject by modulating the phosphorylation of the transcription factor are also included.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE +1
Biphenylcarboxamide derivatives as hedgehod pathway modulators
The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Owner:SUN PHARMA INDS
Androstane derivative, preparation method and applications thereof
ActiveCN110240624AEnhanced inhibitory effectOrganic active ingredientsSteroidsHedgehog signaling pathwayIc50 values
The invention provides an androstane derivative, a preparation method and applications thereof, and belongs to the technical field of medicine. According to the present invention, the androstane derivative has good inhibitory effect on Hedgehog signaling pathway so as to provide an effective treatment drug for patients with chronic myelogenous leukemia; the results of the embodiments show that the androstane derivative has the Hedgehog pathway signaling inhibition average IC50 value measured by using mouse [s12] and human [MZ24] Gli reporter cell lines of 0.020 [mu]m while the average IC50 value of the existing FDA-approved Hedgehog pathway inhibitor is 0.022 [mu]M, such that the androstane derivative has Hedgehog signaling pathway inhibition effect, and further achieve the effect comparable to Vismodegib.
Owner:TIANJIN CHASE SUN PHARM CO LTD
Antitumor medicine
InactiveCN104906113AGrowth inhibitionOrganic active ingredientsSteroidsHedgehog signaling pathwayHuman tumor
The present invention provides jervine or its pharmaceutically acceptable salt thereof as an active ingredient of antitumor drugs. This invention proves jervine strongly inhibits the hedgehog signal pathway and effectively inhibits the tumor growth using three human tumor xenograft models including lung cancer, pancreatic cancer and basal cell carcinoma in nude mice. Jervine has the potential to be a new antitumor agent.
Owner:ZIBO SAIWEI MEDICAL TECH
Regulation of the hedgehog signaling pathway and uses thereof
InactiveUS20070059311A1Eliminate effectiveBacterial antigen ingredientsViral antigen ingredientsHedgehog signaling pathwayViral infection
The present invention provides molecular mechanism leading to the development of cancers associated with hedgehog signaling pathway. These cancers may develop as a result of a chronic bacterial or a chronic viral infection. The present invention provides methods for early detection of such cancers. Additionally, it also provides measures that can be taken to prevent or treat such cancers.
Owner:XIE JINGWU
Anti-neoplastic pharmaceutical composition for targeting hedgehog pathway and cell autophagy
ActiveCN105879034ABroad antitumor activityInhibition of Growth InhibitionAntineoplastic agentsPharmaceutical active ingredientsHedgehog signaling pathwayChronic myelogenous leukemia
The invention belongs to the field of medicine technology, and relates to an anti-tumor pharmaceutical composition targeting hedgehog pathway and autophagy. The drug has a significant synergistic effect in the treatment of solid tumors and non-solid tumors, especially has a very significant anti-tumor effect on drug-resistant chronic myelogenous leukemia. The pharmaceutical composition disclosed by the invention has extensive antitumor activity and has good clinical application prospect.
Owner:FUDAN UNIV
Biphenylcarboxamide derivatives as hedgehod pathway modulators
Owner:SUN PHARMA INDS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com